Investigational new drug applications for oncology in China may see a 60-day deadline for approvals, placing the country on a path already followed by other major Asian countries for rapid early-stage decisions. Industry sources said that in a meeting held by the China FDA's Center for Drug Evaluation this month, the agency told clinical researchers and company executives that a pilot plan is on the drawing board for oncology products because of growing interest and therapeutic need. |
Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Life8/29/2015
|
Daily News
We publish breaking news around the clock on developments in Asia's biotechnology industry. Archives
February 2016
Categories |